Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Endovascular Treatment Devices Market Investments, Share and Revenue Analysis Report with a CAGR of 9.19% From 2024-2031.

 



(Medical-NewsWire.com, July 19, 2024 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Endovascular Treatment Devices Market Size, Share & Trends Analysis Report By Product (Percutaneous Endovascular Aneurysm Repair (EVAR), Fenestrated EVAR, Aortic Stents Biodegradable Stents, Self- Expanding Nitinol Stents, Thoracic Aortic Aneurysm Grafts), By Procedure (Ballon Angioplasty, Angioplasty With Stent Replacement, Drug-Eluting Stents Renal Artery Angioplasty and Stenting Carotid Artery, Thrombosis, Renal Artery Angioplasty and Stenting, Transfemoral Carotid Artery Revascularization, Intravascular Brachytherapy, Carotid Artery Stenting), By Application (Pulmonary, Vascular, Cardiology Surgery, Neurology And Radiology), - Market Outlook And Industry Analysis 2031"

Download Free Demo Report: https://www.insightaceanalytic.com/request-sample/1364

Endovascular treatment devices have revolutionized the landscape of vascular medicine by offering minimally invasive solutions for a variety of conditions. These devices, such as stent grafts for abdominal aortic aneurysm repair and mechanical thrombectomy devices for acute ischemic stroke treatment, enable surgeons to access and treat affected blood vessels through small incisions. This approach not only reduces recovery times and hospital stays but also lowers the risks associated with traditional open surgeries. As the global population ages and the incidence of vascular diseases rises, the demand for these advanced devices continues to grow. Moreover, advancements in device technology further enhance their effectiveness and expand their applications across different cardiovascular conditions, including coronary artery disease and peripheral artery disease.
Looking forward, the market for endovascular treatment devices is poised for significant expansion. Factors such as increasing prevalence of vascular diseases, rising adoption of minimally invasive procedures, and ongoing innovations in device design are driving this growth. These devices not only improve patient outcomes but also contribute to healthcare cost-effectiveness by reducing procedural complications and recovery times. As medical research continues to push boundaries in device innovation and treatment techniques, the role of endovascular treatment devices in modern medicine is set to expand, offering new hope and improved quality of life for patients worldwide.

List of Prominent Players in the Endovascular Treatment Devices Market:
• Cardinal Health
• Endospan
• Geting AB
• Bosten Scientific Corporation
• Inspire MD
• Japan Lifeline Co., Ltd.
• Medtronic
• Lombord Medical
• Penumbra, Inc.
• Terumo Corporation

Market Dynamics:

Drivers-
The global market for endovascular treatment devices is booming, fueled by a rising prevalence of cardiovascular diseases, which claim an estimated 17.9 million lives annually according to WHO. This includes conditions like coronary artery disease, peripheral artery disease, and acute ischemic strokes, driving demand for minimally invasive devices such as stent grafts, catheters, and thrombectomy devices. Concurrently, the increasing incidence of abdominal aortic aneurysms worldwide is accelerating adoption of minimally invasive endovascular aneurysm repair procedures like percutaneous endovascular aneurysm repair (PEVAR) and transcatheter aortic valve repair (TAVR), known for reducing recovery times and hospital stays. Advancements in technology and ongoing R&D efforts are enhancing device efficacy and safety, catering to the healthcare needs of an aging population and bolstering market growth alongside rising healthcare expenditures in developed economies.

Challenges:
High costs associated with endovascular surgeries and devices pose barriers to adoption, impacting healthcare providers and patients. A shortage of skilled surgeons capable of performing complex procedures further limits market growth, while stringent regulatory requirements delay the introduction of innovative devices, hindering industry advancement.

Regional Trends:

North America's leadership in the endovascular treatment devices market is driven by several key factors. The region's high prevalence of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and acute ischemic strokes, underscores the significant demand for advanced treatment options. According to the American Heart Association, cardiovascular diseases remain the leading cause of death in the United States, with 928,741 deaths reported in 2020 alone. Additionally, the aging population in North America contributes to a rising incidence of abdominal aortic aneurysms (AAA), further boosting demand for endovascular devices. Favorable reimbursement policies in the United States and Canada support market growth, while well-established healthcare infrastructure and a skilled workforce enable the proficient delivery of complex procedures.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1364

Recent Developments:

• In July 2024, Endospan secured up to $25 million in loans from Artivion to support the FDA approval process for their Nexus Stent Graft System. Nexus is an off-the-shelf endovascular system aimed at treating aortic arch disease, encompassing aortic aneurysms and aortic dissection. The funding will enable Endospan to advance clinical trials and regulatory efforts necessary to bring this innovative treatment option to market in the United States.

• In April 2024, Getinge received EU MDR approval for its Advanta V12 covered stent system, tailored for treating patients with renal artery stenosis and aortoiliac occlusive disease, including lesions at the aortic bifurcation. This certification confirms compliance with European medical device regulations, underscoring Getinge's dedication to quality and patient safety in vascular interventions.

• In March 2024, Medtronic plc (NYSE: MDT) has FDA-approved its Evolut™ FX+ TAVR system for treating symptomatic severe aortic stenosis. This updated system retains the performance benefits of the Evolut platform and improves coronary access capabilities, offering enhanced treatment options for patients in the U.S.

Segmentation of Endovascular Treatment Devices Market-

By Product:
• Percutaneous Endovascular Aneurysm Repair (EVAR)
• Fenestrated EVAR
• Aortic Stents Biodegradable Stents
• Self- Expanding Nitinol Stents
• Thoracic Aortic Aneurysm Grafts
• Other Devices

By Procedure:
• Ballon Angioplasty
• Angioplasty With Stent Replacement
• Drug-Eluting Stents Renal Artery Angioplasty and Stenting Carotid Artery
• Thrombosis
• Renal Artery Angioplasty and Stenting
• Transfemoral Carotid Artery Revascularization
• Intravascular Brachytherapy
• Carotid Artery Stenting

By Application:
• Pulmonary
• Vascular
• Cardiology Surgery
• Neurology
• Radiology

By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/1364

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.


Insight Ace Analytics

Diana D’souza

+8884144123

diana.dsouza@insightaceanalytics.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC